Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recovery of carotid body function after neuromuscular block recovery
NL-OMON52207Phase 4Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jan 2022
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Sugammadex (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Time to full recovery of hypoxic ventilatory response after recovery of neuromuscular block. Started Jan 2022; status: active, not recruiting.
02
Drugs
Sugammadex
Beyond the preview
Go deeper on NL-OMON52207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52207.